Consumption of caffeine has long been linked to anxiety. The effects of caffeine and the symptoms of anxiety both increase activity within the sympathetic nervous system. Caffeine has been linked to the aggravation and maintenance of anxiety disorders, and the initiation of panic or anxiety attacks in those who are already predisposed to such phenomena. Caffeine usage surpassing 200 mg has been shown to increase the likelihood for anxiety and panic attacks in a population. Excessive amounts of caffeine can result in symptoms from general anxiety to obsessive-compulsive and phobic symptoms.
Caffeine-induced anxiety disorder is a subclass of the DSM-5 diagnosis of substance/medication-induced anxiety disorder. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, or DSM-5, is the current authority for psychiatric diagnosis in the United States. Substance/medication-induced anxiety disorder falls under the category of anxiety disorders in the DSM-5, and not the category of substance-related and addictive disorders, even though the symptoms are due to the effects of a substance.
Diagnosis according to the DSM-5 is dependent on various criteria. Patients must present symptoms of either panic attacks or anxiety. There must also be evidence that the panic or anxiety symptoms are a direct result of the use of the intoxicating substance. In caffeine-induced anxiety disorder, such symptoms would be due to the consumption of caffeine. The DSM-5 makes the distinction that the substance must be physiologically capable of leading to the anxiety and panic symptoms. This establishes the relationship between the abused chemical agent and the observed clinical effects. Caffeine has been proven to act as an antagonist on adenosine receptors, which acts as a stimulant and therefore fulfills this criteria. Symptoms must also not have a more likely clinical cause, such as another type of anxiety disorder, come before the ingestion of the intoxicating substance, or last for an extended amount of time after stopping the use of the substance. Diagnosis also requires that the panic attacks or anxiety due to the use of the intoxicating substance cause a certain amount of disturbance in the patient or lead to deficiency of varying types of daily performance.
In addition to the criteria above, it is important to recognize that the diagnostic criteria for substance/medication-induced anxiety disorder are not met if the symptoms of panic come before the intoxication by the substance. In caffeine-induced anxiety disorder, a diagnosis will not be made if symptoms of anxiety or panic precede the ingestion of caffeine. Also, if symptoms persist for more than one month after substance intoxication, the diagnosis cannot be made. Persistence and continuation of symptoms beyond the initial consumption of caffeine suggest an alternate diagnosis that would better explain the long-lasting symptoms. Anxiety symptoms caused by caffeine are often mistaken for serious mental disorders including bipolar disorder and schizophrenia, leaving patients medicated for the wrong issue. A caffeine-induced anxiety disorder diagnosis should be made, rather than a substance abuse or intoxication diagnosis, when symptoms of panic attacks or anxiety predominate.
Although exact rates of prevalence are not available, general population data shows a 0.002% prevalence over a year-long period and higher prevalence within clinical populations.
Caffeine is a methylxanthine, and is hydrophobic. The structure of caffeine allows the molecule to pass freely through biological membranes including the blood-brain barrier. Absorption in the gastrointestinal tract reaches near completion at about 99% after only 45 minutes. Half-life of caffeine for most adults is between 2.5 and 4.5 hours when consumption is limited to less than 10 mg/kg. However, during neonatal development, half-life for the fetus is significantly longer and decreases exponentially after birth to reach a normal rate at about 6 months. Cytochrome P-450, a hemeprotein, acts in liver microsomes to metabolize caffeine into dimethylxanthines, monomethylxanthines, dimethyl uric acids, monomethyl uric acids, trimethylallantoin, dimethylallantoin, and derivatives of uracil. Most caffeine is metabolized by 3-methyl demethylation, forming the metabolite of paraxanthine. Many metabolites, in addition to caffeine, act within the body and are partly responsible for the physiological response to caffeine.
Mechanism of caffeine action
Caffeine acts in multiple ways within the brain and the rest of the body. However, due to the concentration of caffeine required, antagonism of adenosine receptors is the primary mode of action. The following mechanisms are ways in which caffeine may act within the body, but depending on necessary caffeine concentration and other factors may not be responsible for the clinical effects of the substance.
Mobilization of intracellular calcium
At very high concentrations of about 1–2 mM, caffeine lowers the excitability threshold in muscle cells, leading to prolonged contraction. The introduction of such high doses of caffeine allows calcium to enter the muscle cell through the plasma membrane and sarcoplasmic reticulum more readily. Influx of calcium through the membranes in muscle cells requires at least 250 μM of caffeine. Normally, other toxic effects of caffeine begin to occur in concentrations over 200 μM, however average consumption averages lead to concentrations less than 100 μM. This means that calcium influx and mobilization are most likely not the cause of caffeine's effect on the central nervous system, and are therefore not the cause of caffeine-induced anxiety disorder.
Inhibition of phosphodiesterases
Methylxanthines such as caffeine inhibit the action of cyclic nucleotide phosphodiesterase, which normally acts to break down cAMP. Cyclic adenosine monophosphate, or cAMP, is a second messenger important in many cellular processes and is a critical factor in signal transduction. The inhibition of the phosphodiesterase would lead to a buildup of cAMP, increasing the activity of the second messenger throughout the cell. Though this mechanism is possible, it only occurs after levels of caffeine have reached a toxic level, and therefore it is unlikely to explain the mechanism of caffeine in the brain.
Antagonism of adenosine receptors
There are four well-known adenosine receptors found in the body, A1, A2A, A2B, and A3. The endogenous agonist for these receptors is adenosine, which is a purine nucleoside that is important for processes such as energy transfer in the form of adenosine triphosphate (ATP) and adenosine monophosphate (AMP) and signal transduction in the form of cyclic adenosine monophosphate (cAMP). A2B and A3 receptors require concentrations of caffeine that do not occur at normal physiological levels or with normal levels of caffeine consumption in order to be antagonized, and will therefore not be considered as a possible mechanism for caffeine-induced anxiety.
Caffeine acts as an antagonist of adenosine A1 and A2A receptors. Adenosine is a normal neuromodulator that activates adenosine g-protein coupled receptors. The actions of A1 and A2A receptors oppose each other but are both inhibited by caffeine due to its function as an antagonist.
A2A receptors are coupled to Gs proteins which activate adenylate cyclase and some voltage gated Ca2+ channels. A2A receptors are located in dopamine rich brain regions. A2A receptor mRNA was found in the same neurons as the dopamine receptor D2 within the dorsal striatum, nucleus accumbens and tuberculum olfactorium. A2A receptors are not found in neurons that express the dopamine receptor D1 receptors and Substance P. Within the striatum, part of the basal ganglia, activation of A2A receptors by adenosine increases GABA release, an inhibitory neurotransmitter. When caffeine binds to the receptor, less inhibitory neurotransmitter is released, supporting caffeine's role as a central nervous system stimulant.
A1 receptors are paired with the G-proteins of Gi-1, Gi-2, Gi-3, Go1, and Go2. The g-proteins of A1 receptors continue to inhibit adenylate cyclase, some voltage gated Ca2+ channels, and activate some K+ channels, and phospholipase C and D. A1 receptors are primarily located in the hippocampus, cerebral and cerebellar cortex, and particular thalamic nuclei. Adenosine acts on A1 receptors to decrease opening of N-type Ca2+ channels in some hippocampal neurons, and therefore decrease the rate of firing since Ca2+ is necessary for neurotransmitter release. Caffeine's antagonistic action on the A1 receptor thus decreases the action of adenosine, allowing increased Ca2+ entry through N-type channels and higher rates of neurotransmitter release.
Other actions of caffeine
Though antagonism of adenosine receptors is the primary mechanism of caffeine, Introduction of the methylxanthine into the body also increases the rate of release and recycling of some monoamine neurotransmitters such as noradrenaline and dopamine. Caffeine also has an excitatory effect on mesocortical cholinergic neurons by acting as an antagonist on adenosine receptors that normally inhibit the neuron.
Genetics and variability of caffeine consumption
While many factors contribute to individual differences in a person's response to caffeine, such as environmental and demographic factors (i.e. age, drug use, circadian factors, etc.), genetics play an important role in individual variability. This inconsistency in responses to caffeine can take place either at the metabolic or at the drug-receptor level. The effects of genetic factors can occur either directly by changing acute or chronic reactions to the drug or indirectly by altering other psychological or physiological processes.
Some of these processes include wakefulness, stimulation, and mood and cognition enhancement. Low doses can result in psychological effects of "mild euphoria, alertness, and enhanced cognitive performance"; higher doses produce physiological side effects of nausea, anxiety, trembling, and jitteriness.
There are individuals who are prone to caffeine's anxiogenic effects whilst others are susceptible to its caffeine-induced sleep disturbances and insomnia. Studies with twins have shown that genetics influence individual differences in response to caffeine. Homozygous twins have been found to react in more consistent ways to the caffeine than heterozygous twins.
Caffeine's widespread appeal is due primarily to its mild psychostimulant properties, which increase alertness and cognitive arousal and diminish fatigue. Caffeine also produces a wide range of other symptoms, including upregulation of the cardiovascular system, increased global cognitive processing, and improved physical functioning. Cardiovascular effects can range from increased heart rate and reactivity to severe cardiac arrhythmia. The cognitive effects of caffeine include increased performance in memory, attention, and text reading. The physical effects of caffeine include lowered sensations of pain, less perceived effort, and increased muscle strength and endurance. However, at doses above ~400 mg, both cognitive and physical performance begins to worsen and symptoms of anxiety increase. These anxiety symptoms include persisting insomnia, nervousness, and mood fluctuations.
When undergoing stress, the body activates a system-wide response mechanism known as the HPA axis. This stress signal begins at the level of the hypothalamus in the brain and undergoes subsequent amplifications throughout the body. This system elevates levels of stress hormones in the blood, which results in the body shutting down secondary bodily processes and increasing alertness to better prepare for response to the perceived threat. Studies show that activation of this pathway is correlated with anxiety-like behaviors, including panic, post-traumatic stress, and generalized anxiety disorders, as well as depression. Rodent studies show that caffeine consumption in adolescence results in dysregulation of HPA axis function as well as central nervous system response, which impairs the body's response to stressful stimuli.
In cases of prolonged consumption of excess amounts of caffeine, studies show that individuals exhibit a reduced response to HPA axis activation by the hormone ACTH and a generalized increase in basal levels of stress hormone corticosterone. Researchers concluded that the sensitivity of adrenal glands to ACTH is diminished by caffeine consumption. People diagnosed with panic disorder show less HPA activity following stressful stimuli than their healthy control counterparts.
Caffeine has varying effects on anxiety across given populations. The populations most susceptible to caffeine-induced anxiety disorder include those already diagnosed with an anxiety disorder and adolescents. Adolescents, particularly, are at increased risk for developing anxiety disorders and anxiety-related symptoms. While few human studies have been done to investigate this connection, many rodent studies show a correlation between caffeine consumption in adolescence and increased anxiety. These studies showed that in adolescent rodents exposed to caffeine functioning of serotonin systems was affected, leading to increased anxiety; anxiety-related behaviors were higher than in adult rats exposed to the same amount of caffeine; and reward seeking behaviors as well as mood fluctuations were increased as the rodents matured.
Long-term health effects
To date, there is no evidence to show a connection between caffeine consumption and long-term effects on anxiety. This may be a result of a lack of research investigating this, and not a lack of evidence produced from such studies. However, there is a significant amount of research regarding the long-term health effects of caffeine in general. When consumed in moderation, caffeine can have many beneficial effects. However, over the course of several years, chronic caffeine consumption can produce various long-term health deficits in individuals. Among these, rodent studies have suggested caffeine intake may permanently alter the brain's excitability. As previously stated, long-term effects are most often seen in adolescents who regularly consume excess amounts of caffeine. This can affect their neuroendocrine functions and increase the risk of anxiety-disorder development.
For individuals prescribed anti-anxiety medications such as alprazolam (Xanax), caffeine can introduce further problems by increasing rates of cytotoxicity and cell death by necrosis. This leads to these medications being essentially ruled out as viable treatments for caffeine-induced anxiety. Due to caffeine's negative interaction with anti-anxiety medications such as benzodiazepines, treatments for caffeine-induced anxiety disorder tend to focus on abstinence from or a reduction of caffeine intake and behavioral therapy. Some doctors may recommend a continuance of caffeine consumption but with the provision that the patient actively takes note of physiological changes that happen after caffeine intake. The goal of this approach is to help patients better understand the effects of caffeine on the body and to distinguish threatening symptoms from normal reactions.
- Addicott, MA (2014). "Caffeine Use Disorder: A Review of the Evidence and Future Implications". Current Addiction Reports. 1 (3): 186–192. doi:10.1007/s40429-014-0024-9. PMC 4115451. PMID 25089257.
- Winston, Anthony P.; Hardwick, Elizabeth; Jaberi, Neema (October 2005). "Neuropsychiatric effects of caffeine". Advances in Psychiatric Treatment. 11 (6): 432–439. doi:10.1192/apt.11.6.432. ISSN 2056-4678.
- American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Publishing. pp. 226–230. ISBN 978-0-89042-555-8.
- Torres, Francis M. (April 2009). "Caffeine - Induced Psychiatric Disorders" (PDF). Journal of Continuing Education Topics & Issues. Retrieved 22 February 2016.
- Yang, Amy; Palmer, Abraham A.; de Wit, Harriet (June 9, 2010). "Genetics of caffeine consumption and responses to caffeine". Psychopharmacology. 211 (3): 245–257. doi:10.1007/s00213-010-1900-1. PMC 4242593. PMID 20532872.
- Fredholm, B. B.; Bättig, K.; Holmén, J.; Nehlig, A.; Zvartau, E. E. (1999-03-01). "Actions of caffeine in the brain with special reference to factors that contribute to its widespread use". Pharmacological Reviews. 51 (1): 83–133. ISSN 0031-6997. PMID 10049999.
- Nehlig, Astrid; Daval, Jean-Luc; Debry, Gérard (June 2, 1992). "Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic, and psychostimulant effects". Brain Research Reviews. 17 (2): 139–170. doi:10.1016/0165-0173(92)90012-B. PMID 1356551.
- "Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases". European Review (in Italian). 2013-02-15. Retrieved 2016-04-01.
- Franceschini, Sandro; Lulli, Matteo; Bertoni, Sara; Gori, Simone; Angrilli, Alessandro; Mancarella, Martina; Puccio, Giovanna; Facoetti, Andrea (2020). "Caffeine improves text reading and global perception". Journal of Psychopharmacology. 34 (3): 315–325. doi:10.1177/0269881119878178. hdl:10446/153264. ISSN 0269-8811. PMID 31578918.
- McLellan, Tom M.; Caldwell, John A.; Lieberman, Harris R. (2016). "A review of caffeine's effects on cognitive, physical and occupational performance". Neuroscience & Biobehavioral Reviews. 71: 294–312. doi:10.1016/j.neubiorev.2016.09.001. PMID 27612937.
- Smith, Sean M.; Vale, Wylie W. (2006). "The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress". Dialogues in Clinical Neuroscience. 8 (4): 383–395. ISSN 1294-8322. PMC 3181830. PMID 17290797.
- Trapp, Georgina S.A.; Allen, Karina; O'Sullivan, Therese A.; Robinson, Monique; Jacoby, Peter; Oddy, Wendy H. (2014). "ENERGY DRINK CONSUMPTION IS ASSOCIATED WITH ANXIETY IN AUSTRALIAN YOUNG ADULT MALES: Research Article: Energy-Drink Consumption and Mental Health". Depression and Anxiety. 31 (5): 420–428. doi:10.1002/da.22175. PMID 24019267.
- Ruxton, C. H. S. (2014). "The suitability of caffeinated drinks for children: a systematic review of randomised controlled trials, observational studies and expert panel guidelines". Journal of Human Nutrition and Dietetics. 27 (4): 342–357. doi:10.1111/jhn.12172. PMID 25099503.
- McEwen, Bruce S. (2005). "Glucocorticoids, depression, and mood disorders: structural remodeling in the brain". Metabolism. 54 (5): 20–23. doi:10.1016/j.metabol.2005.01.008. PMID 15877308.
- O’Neill, Casey E.; Newsom, Ryan J.; Stafford, Jacob; Scott, Talia; Archuleta, Solana; Levis, Sophia C.; Spencer, Robert L.; Campeau, Serge; Bachtell, Ryan K. (2016-05-01). "Adolescent caffeine consumption increases adulthood anxiety-related behavior and modifies neuroendocrine signaling". Psychoneuroendocrinology. 67: 40–50. doi:10.1016/j.psyneuen.2016.01.030. PMC 4808446. PMID 26874560.
- Hinton, David J.; Andres-Beck, Lindsey G.; Nett, Kelle E.; Oliveros, Alfredo; Choi, Sun; Veldic, Marin; Choi, Doo-Sup (2019). "Chronic caffeine exposure in adolescence promotes diurnal, biphasic mood-cycling and enhanced motivation for reward in adult mice". Behavioural Brain Research. 370: 111943. doi:10.1016/j.bbr.2019.111943. PMC 6662205. PMID 31095992.
- Arnold, M.R.; Williams, P.H.; McArthur, J.A.; Archuleta, A.R.; O'Neill, C.E.; Hassell, J.E.; Smith, D.G.; Bachtell, R.K.; Lowry, C.A. (2019). "Effects of chronic caffeine exposure during adolescence and subsequent acute caffeine challenge during adulthood on rat brain serotonergic systems". Neuropharmacology. 148: 257–271. doi:10.1016/j.neuropharm.2018.12.019. PMC 6438184. PMID 30579884.
- Ardais, A.P.; Borges, M.F.; Rocha, A.S.; Sallaberry, C.; Cunha, R.A.; Porciúncula, L.O. (2014). "Caffeine triggers behavioral and neurochemical alterations in adolescent rats". Neuroscience. 270: 27–39. doi:10.1016/j.neuroscience.2014.04.003. PMID 24726984.
- Tchekalarova, Jana D.; Kubová, Hana; Mareš, Pavel (2014). "Early caffeine exposure: Transient and long-term consequences on brain excitability". Brain Research Bulletin. 104: 27–35. doi:10.1016/j.brainresbull.2014.04.001. PMID 24727007.
- Saha, Biswarup; Mukherjee, Ananda; Samanta, Saheli; Saha, Piyali; Ghosh, Anup Kumar; Santra, Chitta Ranjan; Karmakar, Parimal (2009-09-01). "Caffeine augments Alprazolam induced cytotoxicity in human cell lines". Toxicology in Vitro. 23 (6): 1100–1109. doi:10.1016/j.tiv.2009.05.018. PMID 19490937.
- "Information on caffeine induced anxiety on MedicineNet.com". MedicineNet. Retrieved 2016-03-31.